XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.19.2

Commitments and Contingencies - Additional Information (Detail) |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
Dec. 05, 2018 USD ($) | Apr. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Feb. 28, 2018 USD ($) | Mar. 31, 2017 USD ($) country | Jun. 30, 2019 USD ($) patent Patent | Jun. 30, 2018 USD ($) | Jun. 30, 2019 USD ($) patent Patent | Jun. 30, 2018 USD ($)
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  | $ 75,000 |  |  |  |  |  |
License fee |  |  |  |  |  | $ 162,500 | $ 250,000 | $ 275,000 | $ 350,000
ADVA Tec Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of patents issued | patent |  |  |  |  |  | 9 |  | 9 |
Number of pending US patent applications | Patent |  |  |  |  |  | 1 |  | 1 |
Number of patents granted | Patent |  |  |  |  |  | 59 |  | 59 |
Number of patent applications in other major markets | Patent |  |  |  |  |  | 4 |  | 4 |
Licensing Agreements | ADVA Tec Agreement | Ovaprene |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Agreement termination period on failing to commercialize in certain designated countries |  |  |  |  | 3 years |  |  |  |
Agreement termination on failing to enroll patient within months of production and release |  |  |  |  | 6 months |  |  |  |
Prior written notice period for termination of agreement for both parties |  |  |  | 60 days |  |  |  |  |
Licensing Agreements | ADVA Tec Agreement | Minimum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of designated European countries | country |  |  |  |  | 3 |  |  |  |
Percentage of royalty rate |  |  |  |  | 1.00% |  |  |  |
Licensing Agreements | ADVA Tec Agreement | Minimum | Ovaprene |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Minimum spending amounts per year |  |  |  |  | $ 5,000,000 |  |  |  |
Licensing Agreements | ADVA Tec Agreement | Maximum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Percentage of royalty rate |  |  |  |  | 10.00% |  |  |  |
Juniper Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Potential annual license maintenance fee, payments in year one |  | $ 50,000 |  |  |  |  |  |  |
Potential annual license maintenance fee payments, thereafter |  | $ 100,000 |  |  |  |  |  |  |
License agreement, period of continuation from date of first commercial sale of product or process |  | 10 years |  |  |  |  |  |  |
License agreement notice period of termination for breach of payment obligation |  | 30 days |  |  |  |  |  |  |
Period of dismissal of bankruptcy petition |  | 90 days |  |  |  |  |  |  |
License agreement notice period of termination for breach of other obligation |  | 60 days |  |  |  |  |  |  |
License agreement, notice period of termination |  | 180 days |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc. | Clinical And Regulatory Milestones |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  | $ 13,500,000 |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc. | Sales Milestones |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  | $ 30,300,000 |  |  |  |  |  |  |
Juniper Pharmaceuticals |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License agreement, termination period prior to receipt of approval |  | 90 days |  |  |  |  |  |  |
Upfront license fee paid |  | $ 250,000 |  |  |  |  |  |  |
SST |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License agreement, termination period due to performance failure |  |  |  |  | 60 days |  |  |  |
Percentage of rights to inventions by employees under license agreement |  |  |  | 50.00% |  |  |  |  |
License agreement, expiration period |  |  |  | 10 years |  |  |  |  |
License agreement, termination period prior to receipt of approval |  |  |  | 90 days |  |  |  |  |
License agreement, termination period after receipt of approval |  |  |  | 180 days |  |  |  |  |
License agreement, termination period for applicable license products of applicable countries |  |  |  | 30 days |  |  |  |  |
SST | Minimum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  | $ 500,000.0 |  |  |  |  |
Secured investment required for license agreement |  |  |  | 10,000,000 |  |  |  |  |
SST | Maximum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  | $ 18,000,000 |  |  |  |  |
SST | License And Collaboration Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Percentage of rights to inventions by employees under license agreement |  |  |  | 50.00% |  |  |  |  |
Orbis | Development And Option Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  | $ 300,000 |  |  |  |  |  |
Commencement period for stage two upon achievement of stage one |  |  | 90 days |  |  |  |  |  |
MilanaPharm | Licensing Agreements |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License fee | $ 25,000 |  |  |  |  |  |  |  |
License fee to be paid upon contingency | 200,000 |  |  |  |  |  |  |  |
Proceeds raised from equity financing | 10,000,000 |  |  |  |  |  |  |  |
MilanaPharm | Assignment Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License fee to be paid upon contingency | 300,000 |  |  |  |  |  |  |  |
Hammock Pharmaceuticals, Inc. | Assignment Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License fee | 250,000 |  |  |  |  |  |  |  |
License fee to be paid upon contingency | 250,000 |  |  |  |  |  |  |  |
Proceeds raised from equity financing | 10,000,000 |  |  |  |  |  |  |  |
Upon Achieving Certain Commercial Milestones | SST | License And Collaboration Agreement | Maximum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  | $ 100,000,000 |  |  |  |  |
Upon Achieving Certain Commercial Milestones | MilanaPharm | Licensing Agreements | Maximum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount | 1,750,000 |  |  |  |  |  |  |  |
Upon Signing Of Development And Option Agreement | Orbis | Development And Option Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  | $ 150,000 |  |  |  |  |  |
Upon Completion Of Fifty Percent Development Not Later Than Six Months | Orbis | Development And Option Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  | $ 75,000 |  |  |  |  |  |
Upon Achieving Certain Clinical And Regulatory Development Milestones | Hammock Pharmaceuticals, Inc. | Assignment Agreement | Maximum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount | $ 1,100,000 |  |  |  |  |  |  |  |
Upon Achievement Of Specified Development And Regulatory Milestones | Licensing Agreements | ADVA Tec Agreement | Maximum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  | $ 14,600,000 |  |  |  |
Upon Reaching Certain Worldwide Net Sales Milestones | Licensing Agreements | ADVA Tec Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  | $ 20,000,000 |  |  |  |
Future Milestone Payments Based On Product Development [Member] | Licensing Agreements | ADVA Tec Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | $ 14,600,000 |
Future Milestone Payments Based On Commercialization [Member] | Licensing Agreements | ADVA Tec Agreement |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | $ 20,000,000 |

X
- Definition Agreement termination on failing to enroll patient within months of production and release. + References No definition available. + Details
Name: | dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement termination period on failing to commercialize in certain designated countries. + References No definition available. + Details
Name: | dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commencement Period For Stage Two Upon Achievement Of Stage One + References No definition available. + Details
Name: | dare_CommencementPeriodForStageTwoUponAchievementOfStageOne
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | dare_CommitmentsAndContingenciesLineItems
Namespace Prefix: | dare_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement expiration period. + References No definition available. + Details
Name: | dare_LicenseAgreementExpirationPeriod
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Notice Period Of Termination + References No definition available. + Details
Name: | dare_LicenseAgreementNoticePeriodOfTermination
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Notice Period Of Termination For Breach Of Other Obligation + References No definition available. + Details
Name: | dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Notice Period Of Termination For Breach Of Payment Obligation + References No definition available. + Details
Name: | dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process + References No definition available. + Details
Name: | dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement, termination period after receipt of approval. + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement, termination period due to performance failure. + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement, termination period for applicable license products of applicable countries. + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement, termination period prior to receipt of approval. + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Fee + References No definition available. + Details
Name: | dare_LicenseFee
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Fee, To Be Paid Upon Contingency + References No definition available. + Details
Name: | dare_LicenseFeeToBePaidUponContingency
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum Potential Milestone Payments + References No definition available. + Details
Name: | dare_MaximumPotentialMilestonePayments
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments, contingent amount. + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Notice period for termination of agreement for both parties. + References No definition available. + Details
Name: | dare_NoticePeriodForTerminationOfAgreementForBothParties
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of designated countries. + References No definition available. + Details
Name: | dare_NumberOfDesignatedCountries
Namespace Prefix: | dare_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patent applications. + References No definition available. + Details
Name: | dare_NumberOfPatentApplications
Namespace Prefix: | dare_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Patents Granted + References No definition available. + Details
Name: | dare_NumberOfPatentsGranted
Namespace Prefix: | dare_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of patents issued. + References No definition available. + Details
Name: | dare_NumberOfPatentsIssued
Namespace Prefix: | dare_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Pending Patents + References No definition available. + Details
Name: | dare_NumberOfPendingPatents
Namespace Prefix: | dare_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of rights to inventions by employees under license agreement. + References No definition available. + Details
Name: | dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement
Namespace Prefix: | dare_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty rate. + References No definition available. + Details
Name: | dare_PercentageOfRoyaltyRate
Namespace Prefix: | dare_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period Of Dismissal Of Bankruptcy Petition + References No definition available. + Details
Name: | dare_PeriodOfDismissalOfBankruptcyPetition
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Annual License Maintenance Fee, Payments In Year One + References No definition available. + Details
Name: | dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential Annual License Maintenance Fee Payments, Thereafter + References No definition available. + Details
Name: | dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds Raised From Equity Financing + References No definition available. + Details
Name: | dare_ProceedsRaisedFromEquityFinancing
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development milestone payment. + References No definition available. + Details
Name: | dare_ResearchAndDevelopmentMilestonePayment
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Secured investment required for license agreement. + References No definition available. + Details
Name: | dare_SecuredInvestmentRequiredForLicenseAgreement
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront License Fee Paid + References No definition available. + Details
Name: | dare_UpfrontLicenseFeePaid
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dare_OvapreneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_OrbisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnCommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |